Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. (APLS) is a leader in developing transformative therapies targeting the complement system, with approved treatments for geographic atrophy and rare blood disorders. This page provides investors and researchers with essential updates on the company’s progress in retinal, hematologic, and renal disease innovation.
Access timely announcements including FDA decisions, clinical trial results, and strategic partnerships that demonstrate Apellis’ commitment to advancing complement immunotherapy. Our curated news collection covers critical developments such as SYFOVRE’s commercial adoption, EMPAVELI’s clinical applications, and research collaborations expanding therapeutic pipelines.
Key updates include regulatory milestones in ophthalmology, hematology treatment expansions, and nephrology research advancements. Bookmark this page to stay informed about Apellis’ pioneering work in C3-targeted therapies and its impact on addressing diseases with limited treatment options.
Apellis Pharmaceuticals (Nasdaq: APLS) announced a conference call and webcast to discuss its first quarter 2023 financial results scheduled for May 4, 2023, at 4:30 p.m. ET. Interested participants must pre-register for the call. The event will be accessible via the company’s website, where a replay will be available for 30 days post-event. As a leader in complement medicine, Apellis focuses on innovative therapies for serious diseases, including geographic atrophy, a major cause of blindness. With a strong pipeline of nearly a dozen clinical and pre-clinical programs, the company is committed to maximizing the potential of targeting C3. For further details, visit their official website.
Apellis Pharmaceuticals (APLS) announced positive results from the Phase 3 OAKS and DERBY studies for SYFOVRE™ (pegcetacoplan injection), the first approved treatment for geographic atrophy (GA) due to age-related macular degeneration (AMD). The analyses presented at the ARVO Annual Meeting demonstrated that SYFOVRE preserved visual function, showing a mean advantage of 5.6 letters in best corrected visual acuity compared to sham, and a 4.1-point improvement in quality-of-life scores. Additionally, SYFOVRE significantly slowed the loss of retinal cells necessary for vision, reducing photoreceptor cell loss by 46-53% and retinal pigmented epithelial cell loss by 20-27%. With marketing applications under review in multiple regions, a decision in the EU is anticipated in early 2024.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced that its marketing applications for intravitreal pegcetacoplan, targeted at treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD), have been validated by regulatory bodies in Canada, Australia, the UK, and Switzerland. Decisions from these authorities are anticipated in the first half of 2024. Following its first approval in the U.S., this move marks a significant step towards worldwide access to pegcetacoplan. The applications were based on Phase 3 OAKS and DERBY study results, demonstrating meaningful reductions in GA lesion growth. Additionally, a marketing authorization application is under review by the European Medicines Agency, with an expected decision in early 2024.
Apellis Pharmaceuticals has launched the GA Won’t Wait™ campaign featuring actor Henry Winkler to raise awareness about geographic atrophy (GA), a serious form of age-related macular degeneration (AMD) affecting one million Americans. The initiative aims to educate older adults on recognizing symptoms of GA and encourage them to seek timely medical advice. Winkler draws from personal experience, having witnessed the devastating effects of AMD on his father-in-law's independence. Symptoms of GA include blurred vision and difficulty with daily tasks, emphasizing the need for early diagnosis and intervention. Apellis stresses that vision loss isn't a natural part of aging, and timely eye health discussions are crucial as individuals age. For further details, visit GAwontwait.com.
Apellis Pharmaceuticals (Nasdaq: APLS) announced the approval of equity inducement awards to seven new employees on April 3, 2023. The awards, totaling 16,115 restricted stock units (RSUs), are designed to incentivize new hires as part of their employment acceptance. The RSUs will vest in increments of 25% annually over four years, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to attract talent in the biopharmaceutical sector, particularly in complement medicine.
As a leader in this field, Apellis aims to innovate therapies for rare and neurological diseases. The company is committed to developing transformative medicines and enhancing its workforce to support ongoing research and development efforts.
